

Repurposing bempedoic acid as a histone deacetylase 6 inhibitor

MERAN KESHAWA EDIRIWEERA¹, PRIYANKA RAJAN² and SOMI KIM CHO²⁻⁴

¹Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo 008, Sri Lanka; ²Subtropical-Tropical Organism Gene Bank, Jeju National University; ³School of Biomaterials Science and Technology, College of Applied Life Science, Jeju National University; ⁴Department of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Republic of Korea

Received December 10, 2022; Accepted April 17, 2023

DOI: 10.3892/ije.2023.15

Abstract. The dysregulation of the activity of histone deacetylase 6 (HDAC6) is observed in a number of human diseases. Targeting HDAC6 has been identified as an ideal treatment strategy in epigenetic-based therapies. Bempedoic acid is an FDA-approved cholesterol-lowering medication. In the present study, bempedoic acid was repurposed as an HDAC6 inhibitor for the first time, at least to the best of our knowledge. Bempedoic acid inhibited the activity of HDAC6 *in vitro* with an IC₅₀ value of ~0.8 mM. *In silico* analysis predicted the formation of hydrogen bonds and hydrophobic interactions between HDAC6 residues and bempedoic acid, which may be attributed to its HDAC6 inhibitory potential. The results of the present study provide new opportunities to bring bempedoic acid into epigenetic-based drug discovery platforms.

Introduction

Drug discovery is a tedious and costly process that requires extensive pre-clinical and clinical evaluations. Although numerous drugs exhibit promising pre-clinical efficacies, their clinical efficacies may be unfavorable, resulting in the omission of pre-clinically favorable drug candidates in clinical drug development settings (1,2). Drug repurposing approaches identify novel pharmacological targets of drug candidates that have already obtained regulatory approval for clinical use (3). As the safety, pharmacodynamic and pharmacokinetic profiles of clinically approved drug candidates are already established, the exploration of novel pharmacological properties or targets provides a number of benefits in terms of the cost associated with drug discovery approaches and opens up new arenas in modern drug discovery landscapes (3).

Bempedoic acid was approved by the Food and Drug Administration (FDA) in 2020 for the treatment of refractory hypercholesterolemia (4). Bempedoic is a pro-drug that is activated in the liver by the enzyme very long-chain acyl-CoA synthetase (ACSVL1). The active form of bempedoic acid (bempedoic acid attached to coenzyme A) is an ATP lyase inhibitor (5). ATP lyase plays a key role in cholesterol biosynthesis (6). By inhibiting the activity of ATP lyase, bempedoic acid upregulates the expression of low-density lipoprotein (LDL) cholesterol receptors, decreasing LDL-cholesterol by increasing cholesterol uptake and clearance in the liver (6).

According to epigenetics, chromatin-bound information, other than the information available in DNA sequences, is responsible for the regulation of gene expression (7). Notably, dysregulated epigenetic events are commonly observed in human diseases, rendering them attractive pharmacological targets (8). Of the various epigenetic events, histone acetylation has been well-characterized. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are involved in the acetylation of histones. HATs mediate acetylation reactions, while HDACs mediate deacetylation reactions in a well-balanced and reversible manner (7). Thus far, 18 different HDACs have been identified in humans (9). There is ample evidence to indicate that HDAC6 plays a key role in a wide range of human diseases, including cancer, neurological diseases, inflammatory diseases and metabolic diseases, thus rendering it an attractive drug target (10,11). To date, various HDAC6 inhibitors have been identified from natural and synthetic sources. The HDAC inhibitory effects of fatty acids have been well-established and numerous fatty acids have been shown to exert HDAC inhibitory effects at millimolar concentrations (i.e., effective concentration for inhibiting HDAC activity) (9,12,13).

The chemical structure of bempedoic acid resembles an α,ω -dicarboxylic acid (14). In a recent study, the authors identified a series of odd-chain fatty acids as HDAC6 inhibitors, which motivated the exploration of the HDAC6 inhibitory effects of new fatty acid candidates (15). Considering the recent findings related to the HDAC6 inhibitory potential of odd-chain fatty acids and the chemical structure of bempedoic acid, it was hypothesized that bempedoic acid can exert HDAC6 inhibitory effects. This hypothesis was tested using a cell-free HDAC6 enzyme assay and confirmed by *in silico* analysis.

Correspondence to: Professor Somi Kim Cho, School of Biomaterials Science and Technology, College of Applied Life Sciences, Jeju National University, 102 Jejudaehak-ro, Jeju-si, Jeju 63243, Republic of Korea
Email: somikim@jejunu.ac.kr; phd.kim.somi@gmail.com

Key words: bempedoic acid, histone deacetylase 6 inhibition, epigenetics, drug repurposing

Materials and methods

Chemicals. Bempedoic acid was purchased from Cayman Chemical Company (item no. 26409).

HDAC6 enzyme inhibitory assay. A BioVision HDAC6 Enzyme Cell-Free Inhibitory Assay kit (cat. no. K465; BioVision, Inc.) was used to evaluate the HDAC6 inhibitory potential of bempedoic acid. The assay procedures provided by the manufacturer were followed when conducting the enzyme assays. This HDAC6 enzyme inhibitory assay kit includes HDAC6 synthetic acetylated peptide substrate, human HDAC6 enzyme and a developer. Prior to the assay, bempedoic acid was dissolved in ethanol to yield a dilution series starting from 2 to 0.0078 mM. Fluorescence was measured at excitation/emission wavelengths of 380/490 nm using a microplate reader (Sunrise; Tecan Group, Ltd).

Molecular docking. The crystal structure of HDAC6 comprising nexturastat A was obtained from the Protein Data Bank (PDB ID: 5G0J). Prior to docking, nexturastat A was removed from the active site of HDAC6. The three-dimensional (3D) structure of bempedoic acid (CID: 10472693) was obtained from the PubChem database and energetically pre-optimized using the universal force field (PyRx Python Prescription, version 0.8; The Scripps Research Institute, 2008). The amino acids in the active site were determined using the Computed Atlas for Surface Topography of Proteins (16) and BIOVIA Discovery Studio 4.5 (Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Version 4.5. San Diego; Dassault Systèmes; 2015). The docking experiments were performed using the AutoDock Vina module (Molecular Graphics Lab, The Scripps Research Institute). Based on the binding energies, the best-docked pose was selected and 3D images were generated using PyMOL (The PyMOL Molecular Graphics System, Ver.2.5.0; Schrodinger, LLC). The docked complex of HDAC6 was further optimized, validated and explored using the Discovery Studio visualizer (version 21.1.0.20298). The hydrogen bonds and hydrophobic interactions between bempedoic acid and HDAC6 were analyzed using the LigPlot program (17).

Data analysis. The enzyme inhibitory assay was conducted in triplicate. The results are presented as the mean \pm standard deviation (SD). GraphPad Prism software was used to generate enzyme inhibitory graphs and to obtain the half maximal inhibitory concentration (IC_{50}) of bempedoic acid.

Results

HDAC6 enzyme inhibitory effects of bempedoic acid. The effect of bempedoic acid on HDAC6 activity was assessed *in vitro*. As illustrated in Fig. 1, bempedoic acid exerted a concentration-dependent HDAC6 inhibitory effect with an IC_{50} value of ~ 0.8 mM.

Molecular docking. For *in silico* analysis, the 3D structure of *Danio rerio* HDAC6, 5G0J.pdb, was used as the 3D structure of *Homo sapiens* HDAC6 (containing two catalytic domains) has not been deposited in the PDB (15). The basic molecular




Figure 1. The HDAC6 inhibitory effects of bempedoic acid *in vitro*. Bempedoic acid exhibited an IC_{50} value of ~ 0.8 mM. HDAC6, histone deacetylase 6.

structure of HDAC6 contains two catalytic domains (CD1 and CD2) (18). Among these catalytic domains, CD2 exhibits broad substrate specificity and has been used exclusively to develop HDAC6-selective inhibitors (19). The docking of bempedoic acid to HDAC6 exhibited binding energies ranging from -4.7 to -5.1 kcal/mol. The complex with the lowest binding energy was selected for further analysis. As shown in Fig. 2, bempedoic acid is docked into the active pocket of the catalytic domain of HDAC6.

LigPlot analysis revealed molecular interactions (hydrogen bonds and hydrophobic interactions) between bempedoic acid and the catalytic domain of HDAC6 (Fig. 3). Furthermore, the LigPlot analysis revealed that five residues, Gln352, Val175, Leu180, Ser765 and Arg181, are involved in hydrogen bonds, and six residues, Ser768, Arg354, Ser178, Ala60, Lys59 and Asp764, are involved in hydrophobic interactions with bempedoic acid. These hydrogen bonds and hydrophobic interactions may play an essential role in lead optimization and may thus enhance the affinity of bempedoic acid for HDAC6.

Discussion

In the present study, for the first time, to the best of our knowledge, bempedoic acid was repurposed as a HDAC6 inhibitor. Bempedoic acid is an FDA-approved cholesterol-lowering agent (4). In the liver, with the aid of the enzyme ACSVL1, bempedoic acid is converted to its active form, which is an ATP citrate lyase inhibitor (5). The dysregulated activity or overexpression of HDAC6 have been reported in a range of human diseases, rendering HDAC6 an interesting drug target (10,11).

A large number of isoform-specific and pan-HDAC inhibitor proteins belonging to four major chemical classes have been identified: Benzamides, fatty acids, hydroxamates and cyclic tetrapeptides (7). A recent study by the authors identified a series of odd-chain fatty acids, including valeric acid (C5:0), heptanoic acid (C7:0), nonanoic acid (C9:0), undecanoic acid (C11:0) and pentadecanoic acid (C15:0) as HDAC6 inhibitors (15). Of these, pentadecanoic acid exerted more potent HDAC6 inhibitory effects with binding energies




Figure 2. Docking results for bempedoic acid and HDAC6 obtained from AutoDock Vina. (A) A three-dimensional image of bempedoic acid docked into the active pocket in the catalytic domain of HDAC6. (B) A closer view of bempedoic acid binding to the catalytic domain of HDAC6. HDAC6, histone deacetylase 6.




Figure 3. The molecular interactions between bempedoic acid and histone deacetylase 6 were analyzed using LigPlot. Hydrophobic interactions are represented by brick red spokes arcs. Hydrogen bonds are indicated by green dotted lines. Receptor residues involved in hydrogen bonding are indicated in green. Ligand residues (oxygen atoms in bempedoic acid) involved in hydrogen bonding are shown in red.

ranging from -3.95 to -2.90 kcal/mol. The HDAC3 and HDAC7 enzyme inhibitory effects of short-chain fatty acids (namely, valeric, propionic, butyric, caproic and 4-methylvaleric acids) have been previously investigated (20). Butyric acid was

identified as the most potent HDAC3 inhibitor among the fatty acids tested. Fass *et al* (21) demonstrated the class I and class IIa HDAC inhibitory potentials of the short-chain fatty acids, butyric acid and valproic acid. The branched-chain fatty acids

2,2-dimethylbutyric acid, 2-ethylbutyric acid, and valproic acid, and the un-branched fatty acids propionic acid, valeric acid and butyric acid, were previously identified as weak and equipotent HDAC inhibitors, respectively (22). In a recent study, valeric acid was identified as a HDAC3 inhibitor (23).

In the present study, the *in vitro* HDAC6 enzyme inhibitory assay indicated that bempedoic acid can inhibit the activity of HDAC6 at millimolar concentrations. According to the *in silico* findings, bempedoic acid docked into the active pocket of the catalytic domain of HDAC6 and was involved in the formation of hydrogen bonds and hydrophobic interactions with HDAC6 residues, which may explain the HDAC6 inhibitory effects of bempedoic acid. Notably, bempedoic acid exhibited a lower binding energy (-4.7 to -5.1 kcal/mol) compared to pentadecanoic acid, which was identified as the most potent HDAC6 inhibitor in a recent by the authors (15).

Bempedoic acid is rapidly absorbed in the small intestine and reaches a maximum plasma concentration of $20.6 \pm 6.1 \mu\text{g/ml}$ (0.059 mM) following multiple-dose administration at 180 mg/day (24). According to the enzyme assay results of the present study, bempedoic acid at concentrations near ~0.059 mM also exerted HDAC6 inhibitory effects, indicating that the HDAC6 inhibitory action of bempedoic acid is likely to occur in body tissues. According to the FDA drug label for bempedoic acid, bempedoic acid and its conjugates are detected in plasma, with bempedoic acid being the most prominent compound, accounting for almost 46% of the area under the curve ($\text{AUC}_{0-48 \text{ h}}$) (25). Although the pre-clinical findings are meaningful, it is critical to assess the HDAC isoform specificities of bempedoic acid, its active form and conjugates. Moreover, the preliminary findings of the present study may provide an important foundation with which to rationalize the HDAC6 inhibitory effects of bempedoic acid and warrant additional investigations to explore the detailed epigenetic mechanisms associated with bempedoic acid and its active form in cell-based systems. A recent study demonstrated that bempedoic acid can reprogram the epigenetic and transcriptional machineries of ATP citrate lyase-associated genes in hepatocytes (26), further supporting the current preliminary experimental findings. Taken together, the present study opens up new perspectives for the exploration of the epigenetic effects of bempedoic acid in human diseases, as HDAC6 activity and expression are frequently altered in a range of human diseases (10,11).

In conclusion, to the best of our knowledge, the present study reports for the first time that bempedoic acid, an FDA-approved cholesterol-lowering drug, functions as an HDAC6 enzyme inhibitor. Similar to several other fatty acids, bempedoic acid exerts HDAC6 inhibitory effects at millimolar concentrations.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education

(no. 2016R1A6A1A03012862) and the UNESCO-TWAS and the Swedish International Development Cooperation Agency (Sida; no. 22-140 RG/BIO/AS_I).

Availability of the data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

MKE and SKC designed the study. PR and MKE performed the experiments. MKE and PR analyzed the data and wrote the manuscript. SKC supervised the study and revised the manuscript. All authors have read and approved the final manuscript. MKE and SKC confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Hughes JP, Rees S, Kalindjian SB and Philpott KL: Principles of early drug discovery. *Br J Pharmacol* 162: 1239-1249, 2011.
2. Ediriweera MK, Tennekoon KH and Samarakoon SR: In vitro assays and techniques utilized in anticancer drug discovery. *J Appl Toxicol* 39: 38-71, 2019.
3. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guillems T, Latimer J, McNamee C, *et al*: Drug repurposing: Progress, challenges and recommendations. *Nat Rev Drug Discov* 18: 41-58, 2019.
4. Marrs JC and Anderson SL: Bempedoic acid for the treatment of dyslipidemia. *Drugs Context* 9: 2020-6-5, 2020.
5. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL and Ballantyne CM; CLEAR Harmony Trial: Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med* 380: 1022-32, 2019.
6. Feng X, Zhang L, Xu S and Shen AZ: ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. *Prog Lipid Res* 77: 101006, 2020.
7. Ediriweera MK, Tennekoon KH and Samarakoon SR: Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. *Drug Discov Today* 24: 685-702, 2019.
8. Hatchwell E and Grealley JM: The potential role of epigenomic dysregulation in complex human disease. *Trends Genet* 23: 588-95, 2007.
9. Ediriweera MK and Cho SK: Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. *Pharmacol Ther* 206: 107437, 2020.
10. Pulya S, Amin SA, Adhikari N, Biswas S, Jha T and Ghosh B: HDAC6 as privileged target in drug discovery: A perspective. *Pharmacol Res* 163:105274, 2021.
11. Batchu SN, Brijmohan AS and Advani A: The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. *Clinical Sci* 130: 987-1003, 2016.
12. Waldecker M, Kautenburger T, Daumann H, Busch C and Schrenk D: Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. *J Nutr Biochem* 19: 587-593, 2008.

13. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: Molecular mechanisms of action. *Oncogene* 26: 5541-5552, 2007.
14. Oniciu DC and Myers JL: Bempedoic acid and the fraudulent fatty acid family: The gold rush to cardiovascular therapies in the new millennium. *Org Process Res Dev* 25: 365-372, 2021.
15. Ediriweera MK, To NB, Lim Y and Cho SK: Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors. *Biochimie* 186: 147-156, 2021.
16. Tian W, Chen C, Lei X, Zhao J and Liang J: CASTp 3.0: Computed atlas of surface topography of proteins. *Nucleic Acids Res* 46: W363-W367, 2018.
17. Laskowski RA and Swindells MB: LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model* 51: 2778-2786, 2011.
18. Osko JD and Christianson DW: Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. *Bioorg Med Chem Lett* 30: 127023, 2020.
19. Osko JD and Christianson DW: Structural basis of catalysis and inhibition of HDAC6 CD1, the enigmatic catalytic domain of histone deacetylase 6. *Biochemistry* 58: 4912-4924, 2019.
20. Ho RH, Chan JC, Fan H, Kioh DY, Lee BW and Chan EC: In silico and in vitro interactions between short chain fatty acids and human histone deacetylases. *Biochemistry* 56: 4871-4878, 2017.
21. Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, Reis SA, Klein PS, Mazitschek R, Maglathlin RL, *et al*: Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. *ACS Med Chem Lett* 2: 39-42, 2010.
22. Gilbert KM, DeLoose A, Valentine JL and Fifer EK: Structure-activity relationship between carboxylic acids and T cell cycle blockade. *Life Sci* 78: 2159-2165, 2006.
23. Han R, Yang H, Li Y, Ling C and Lu L: Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. *Medical Oncol* 39: 213, 2022.
24. Markham A: Bempedoic acid: First approval. *Drugs* 80: 747-753, 2020.
25. Esperion Therapeutics Inc.: NEXLETOL (bempedoic acid): tablets, for oral use. Initial U.S. Approval: 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s0001bl.pdf. Accessed December 12, 2022.
26. Rose A, Rodriguez-Aguilera JR, Schicht G, Lohrenz A, Tvardovskiy A, Büscher J, Hoffmann A, Damm G, Laufs U, Seehofer D, *et al*: The impact of cholesterol lowering drugs on metabolism and epigenetics. *Atherosclerosis* 355: 179-180, 2022.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.